Craig-Hallum raised the firm’s price target on Avadel Pharmaceuticals to $20 from $18 and keeps a Buy rating on the shares. Both the anticipated Q4 results and the launch KPIs point to a continuation of strong momentum in 2024, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AVDL:
- Avadel Pharmaceuticals price target raised to $27 from $25 at Oppenheimer
- Avadel Pharmaceuticals provides update on LUMRYS launch performance
- Avadel Pharmaceuticals sees FY23 net product revenue $28M
- Avadel Pharmaceuticals named 2024 To Pick at Needham
- Avadel Pharmaceuticals named 2014 To Pick at Needham
